We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

The agency had for years said it could not conclude whether COVID-19 was the result of a lab incident or it originated in ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely expected by ...

“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

12 large-cap stocks saw significant gains last week, including Summit Therapeutics, Rocket Lab, Moderna, and Netflix. Analysts raised price forecasts.

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by ...

Moderna lowered its 2025 sales guidance by roughly $1 billion, as it continues to cut costs. The biotech company now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most ...